The advances include optimized prime editing guides RNA (pegRNA), which were shown in recent research published online in Nature Biotechnology to significantly improve the editing process for gene targets, according to the company (Nature Biotechnology, October 4, 2021).

In addition, Prime Medicine said that it is pursuing recently described strategies for improving efficiency by modulating a specific DNA repair pathway: the mismatch repair pathway. Research published in Cell revealed that this pathway can substantially enhance prime editing efficiency, according to the vendor (Cell, October 14, 2021).

By modulating the mismatch repair pathway through several approaches, editing activity could be increased severalfold and undesired byproducts could be decreased, Prime Medicine said.

The company said it holds commercial rights from the Broad Institute of MIT and Harvard University to use the Prime Editing technology for human therapeutic applications. Scientists and other companies around the world continue to use Prime Editing for research and other applications, Prime Medicine said.

Cell and gene therapy firms see over $13.6B so far in 2021
Rapid financing activity in the cell and gene therapy industry has exceeded $13 billion in 2021. Over half of this funding is from venture capital and...

Prime Medicine launches with gene editing technology
Prime Medicine has launched with $315 million in financing to rapidly advance its prime editing gene editing technology.